Buy KLOW Blend 80 mg in Australia
In Australia, KLOW 80 mg is supplied by Australian Research Peptides to laboratories and researchers — $189.99, out of stock at present. KLOW is a four-peptide blend, the blend buyers describe as GLOW plus KPV, in one lyophilised vial. GHK-Cu, BPC-157, TB-500 and KPV are dried together into a single cake at a nominal ~50/10/10/10 mg split rather than an assayed one. Its research context spans cell migration and inflammatory signalling, with GHK-Cu carrying most of the mass. Post reaches every Australian state and territory. In vitro research purposes only.
Copper Peptide Research · Lyophilised Powder · Independently lab-tested · SKU 92659
$189.99
Presentation
80 mg per vial
Grade
Research Grade
Form
Lyophilised Powder
Category
Copper Peptide Research
Currently out of stock — stocked lines dispatch same business day before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. ARP gives no usage, medical or therapeutic guidance of its own.
KLOW · 80 mg
$189.99
In stock in the same research category: GHK-Cu 100 mg
KLOW is out of stock. GHK-Cu is in the same research category and is available now.
View GHK-Cu 100 mgBrowse all Copper Peptide Research
About KLOW
All four peptides in a KLOW vial come out of preclinical research, and each carries its own separate literature. GHK-Cu is examined in cell culture against extracellular-matrix proteins. BPC-157 and TB-500 are examined in angiogenesis and cell migration assays. KPV is examined in cultured human cell lines, where the readout is inflammatory signalling. No published study tests the four together, so each research field named here belongs to a component rather than to the mixture. Combining them in one container is a packaging choice. Nothing here says four peptides sharing a vial behave differently from four kept apart.
KLOW is a name rather than a compound, and this category lists it as a single-vial blend. The letters cover the three peptides in GLOW, namely GHK-Cu, BPC-157 and TB-500, with KPV added as a fourth. At the nominal split this page publishes, the copper peptide is roughly five parts in eight of the vial. Because the letters describe no fixed recipe, two products carrying them can differ, and only the compound list and the total quantity settle what either one is.
KPV is what separates KLOW from GLOW. It is a chain of three amino acids, lysine then proline then valine, taken from the tail end of alpha-MSH. Its published work sits in inflammation rather than in structural repair, which is why a four-peptide vial reaches across two research fields where a three-peptide one reaches across one. All four also hold their own listings here, so the blend can be set against its own parts.
BAC water (bacteriostatic water) is also in our range.
The peptide calculator works out the mg/mL concentration of a reconstituted vial.
What is in the vial
| Component | Amount per vial |
|---|---|
| GHK-Cu — the copper(II) complex of the GHK tripeptide, and the largest component by mass in the blend | ~50 mg |
| BPC-157 — a fifteen-amino-acid peptide, sequence GEPPPGKPADDAGLV per PubChem CID 9941957 | ~10 mg |
| TB-500 — the seven-amino-acid actin-binding fragment of thymosin beta-4, not the full 43-residue protein | ~10 mg |
| KPV — Lys-Pro-Val, the C-terminal three residues of alpha-MSH, and the peptide that distinguishes KLOW from GLOW | ~10 mg |
| Total | 80 mg per vial |
KLOW specifications, storage and shipping
- Compound: KLOW
- Also known as: GHK-Cu, BPC-157, TB-500 and KPV combination
- Class: Four-peptide blend
- Appearance: Lyophilised powder
- Sizes & SKUs: 80 mg (92659)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: Research grade
- Testing: Independently lab-tested before release
- Identity confirmation: Mass spectrometry
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
KLOW is independently lab-tested before release. No laboratory report is published for this line yet. The COA library lists every product and strength, and says which reports are available.
This line is currently out of stock. Stocked lines ordered before 12pm Sydney time on a business day are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about KLOW
This question guide from Australian Research Peptides covers KLOW in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
KLOW 80 mg is dispatched anywhere in Australia by Australian Research Peptides, with tracking on both Express Post and standard post to every state and territory. One sealed vial holds the four-peptide cake of GHK-Cu, BPC-157, TB-500 and KPV, and each of those four also has its own ARP listing. There is no KLOW vial to send right now, though the weekday 12pm Sydney time cut-off holds once one is back, moving entirely within Australia, so customs never sees the parcel.
KLOW puts GHK-Cu, BPC-157, TB-500 and KPV into one 80 mg vial, so the honest comparison is against four separate Australian Research Peptides listings at whatever each of them carries on the day. One thing makes that sum awkward: the smallest GHK-Cu listing ARP carries is a 100 mg vial, so matching the copper-peptide share of a KLOW vial means buying roughly twice what the blend holds. Buying apart buys back control, because the ratio inside KLOW is fixed at blending and four separate vials can be varied.
One KLOW vial lands just under the free Standard tracked post mark — close enough that a small second item usually carries the order over. Two vials clear both that threshold and the higher Express Post one in a single step, which no other four-peptide order in Australian Research Peptides' range manages. Qualification is judged on the goods subtotal before any discount code, so a code can never push an order back below either mark.
KLOW is ordered from Australian Research Peptides online, with no phone line to call and no counter to visit. The four-peptide vial comes in a single 80 mg size, so there is one stock position to follow rather than several. Payment is by PayID or bank transfer and by nothing else, with the order reference quoted so the payment can be matched. Delivery is tracked, to any Australian address.
PayID is a bank-run service, not a third party: it maps a phone number, email or ABN to an existing Australian bank account so a KLOW payment moves directly between banks over the New Payments Platform. You initiate it inside your own banking app, and Australian Research Peptides receives money without ever holding a payment credential of yours. The order reference goes in the description, because that is the only thing tying the transfer to the order.
Choose KLOW when the work wants a component studied in inflammation alongside the three studied in repair, and GLOW when three are enough. The four-peptide vial is the wider net and the harder one to attribute a result to, because a mixture of four offers four candidate explanations for anything observed. Neither choice can be unpicked afterwards: the ratio in each vial is fixed at blending, so isolating a component means buying that peptide on its own listing.
Identity, names and exact format
KLOW is a four-peptide blend supplied as one freeze-dried cake in a single 80 mg vial, and what is in it is GHK-Cu, BPC-157, TB-500 and KPV. Those are the three peptides GLOW holds, plus KPV, which is where the leading K in the name comes from. Three of them sit in cell-signalling and extracellular-matrix research and KPV sits in inflammation research, so one vial reaches into two fields rather than one.
KLOW's GHK-Cu component has been examined at picomolar concentrations in cultured fibroblasts. A 1988 FEBS Letters paper measured collagen synthesis in the dish across a concentration range, with the response beginning between 1 and 10 pM and peaking at 1 nM. Cell numbers did not change over that range. Those are concentrations in glassware, not amounts given to a living animal.
An 80 mg KLOW vial is made to a four-way recipe: roughly 50 mg of GHK-Cu, then roughly 10 mg each for BPC-157, TB-500 and KPV. Those four figures are nominal formulation amounts that the KLOW name carries across this category, and they sum exactly to the mass printed on the label. They are not an assay of the vial in front of you, which is why each keeps a tilde. A per-component number printed to two decimal places would claim a measurement nobody has taken. If the exact division matters for the work, ask before ordering.
The address entered on a KLOW stock alert is used for that one message and nothing else — no newsletter, no promotions, no sharing with anyone. It is a single-purpose record against a single product line, and it is not the same thing as having an account or a marketing subscription.
An eighty-milligram KLOW vial carries a visible quantity by any measure, and the GHK-Cu fraction runs a blue tone through the dried mass, so the concern rarely arises. What buyers do report instead is a cake broken loose and rattling as fragments. Freeze-dried solids are brittle and travel poorly intact; fractured material dissolves exactly as an undisturbed one does.
In composition terms, yes — KLOW is GLOW plus KPV, and the extra ten milligrams on the label is that fourth peptide rather than more of the other three. GLOW holds GHK-Cu, BPC-157 and TB-500 across 70 mg; KLOW holds the same three and adds KPV, a chain of three amino acids drawn from alpha-MSH, across 80 mg. KPV's published work sits in inflammation research rather than in structural repair, which is what widens the research field one vial reaches.
Research context and evidence
KLOW stands for the four peptides in the vial: KPV added to the three that make up GLOW, which are GHK-Cu, BPC-157 and TB-500. No standards body defines the word, so nothing obliges two suppliers using it to fill a vial the same way. Read the named component list and the total milligrams rather than the four letters, because that is what settles what a given vial actually is.
The KLOW blend is four research peptides freeze-dried into one 80 mg vial rather than four separate vials. The four are GHK-Cu, BPC-157, TB-500 and KPV. One container means one storage decision, one diluent volume and one reconstitution instead of four. What it costs is control, because the ratio is fixed when the blend is made and no single component can be raised or dropped inside the vial.
KLOW has no single mechanism, because four peptides in one vial carry four separate molecular targets and four separate literatures behind them. GHK-Cu binds copper(II) and is examined in cell culture against collagen and elastin synthesis. TB-500's seven-amino-acid motif is the actin-binding region of thymosin beta-4. BPC-157 is described in the literature against Akt-eNOS and VEGFR2 signalling. KPV enters cells through a peptide transporter and is studied against NF-kappaB and MAP kinase signalling.
The research areas KLOW's four peptides sit across are cell migration, inflammatory signalling, gut-lining and barrier work, and extracellular-matrix biology. GHK-Cu is the component with an extracellular-matrix research record, while KPV is what pulls the blend toward inflammation and immune-regulation research. No study has examined the four together, so each of those areas belongs to a component rather than to the mixture.
No published study tests KLOW as a blend, and that absence is the single most useful fact on this page. Each of the four peptides carries its own separate preclinical file, and stacking four files does not produce a result about the blend. TB-500's actin-binding motif is characterised in endothelial cell assays at nanomolar concentrations. GHK-Cu is characterised in fibroblast culture and KPV in cultured human cell lines. None of that is a controlled human result, and Australian Research Peptides makes no claim beyond the vial's identity.
KLOW carries four peptides and not one shared stability figure. Only BPC-157 has a published plasma stability number, beneath thirty minutes, per Mateescu's 2026 Pharmaceutics review. The thymosin fragment, the copper tripeptide and KPV each lack that measurement. Nothing in the literature characterises a four-way mixture at all, so a stated duration would be fabrication dressed as evidence.
There is no single count for KLOW, because four separate chains share the vial. BPC-157 is fifteen, sequence GEPPPGKPADDAGLV in PubChem. The TB-500 fragment is seven, LKKTETQ, sitting at positions 17 to 23 of mature thymosin beta-4 (UniProt). GHK is three, glycine then histidine then lysine. The copper rides on that chain and is not itself an amino acid. KPV is three, lysine then proline then valine.
KPV is the peptide that pulls KLOW toward inflammation research. It is lysine, proline and valine, the final three amino acids of alpha-MSH. Unlike the other three components it is a bare tripeptide, with no copper centre and no long chain, and in cultured human cell lines it is studied against NF-kappaB and MAP kinase, two of the switches a cell uses to turn inflammation on. That is a different research area from the other three, which is what a four-peptide vial reaches that a three-peptide one does not.
Handling, storage and measurements
Every peptide in a KLOW vial contains lysine, so the whole powder pulls in moisture. Keep the sealed vial dry, dark and cold, below -15 °C for anything long-term. Let it reach room temperature in a desiccator before you open it. Only the TB-500 part carries glutamine, one of the five amino acids that make holding a peptide in solution risky. Reconstituted material is therefore not for keeping.
KLOW dissolves as one powder rather than as four separate steps, because the four peptides were dried together into a single cake. An aqueous diluent is the usual choice, and one volume of it covers the lot. Run it down the inside wall of the vial instead of straight onto the cake, then swirl gently rather than shaking. Whatever volume goes in fixes the strength of the solution. Keep the result cold and split it into aliquots.
Reconstituted KLOW carries Australian Research Peptides' chilled working life of 8 to 12 weeks at fridge temperature, 2-8 °C, with the earliest of its four peptides to degrade setting that date for all of them. Only the TB-500 component finishes on glutamine, which Bachem names among the residues that shorten a peptide in solution; the other three carry none of them. No stability study has been published on four peptides sharing one cake, so treat that window as a handling limit rather than a measured survival. An 80 mg vial is a lot to get through.
No fill volume is published for the KLOW 80 mg vial, because the volume belongs to the work rather than to the product. Whatever goes in applies to all four peptides together and never to one of them on its own. The four component masses printed on this page describe the recipe the name is made to, not a reading taken from your own vial, so they will not divide into four trustworthy separate concentrations.
KLOW dries four peptides into one cake, and that dissolves more slowly than any single compound, so the intermediate stage can look wrong when it is not. Copper supplies the blue tint, which should remain see-through. Bubbles raised by handling fade without help. Material still suspended once the liquid has warmed and settled is undissolved solid, and a preparation like that should be discarded.
KLOW arrives as a dry cake and is taken into solution with an aqueous diluent for laboratory work. One volume of it covers all four peptides, because they were dried together, and that volume sets one combined concentration. No liquid forms any part of what a KLOW vial holds.
KLOW comes from Australian Research Peptides Pty Ltd, an Australian company selling direct rather than reselling an overseas listing. KLOW is independently lab-tested before release, and ARP's CoA library records which products and strengths have a certificate published. ARP also publishes a component table naming all four peptides in the vial. Orders settle by PayID or bank transfer and post nationwide — and once a vial is back, one beating 12pm Sydney time leaves that business day.
KLOW carries one Australian-dollar figure for the vial, and there is no second size to compare it against, because the 80 mg vial is the whole listing. That removes the per-milligram comparison a multi-strength page invites, so the useful read is against another multi-peptide vial and its total milligrams rather than against a one-peptide listing. The figure itself, and whether the vial can ship today, are read live from Australian Research Peptides' stock and price records.
Testing and batch documents
KLOW is independently lab-tested before Australian Research Peptides supplies it, and four peptides make that job harder than one. Mass spectrometry has four expected masses to account for rather than one. What that establishes is the identity of the batch that was tested, and nothing about any other batch.
Ordering, payment and Australian delivery
A KLOW parcel is 1–2 business days away by Express Post in the fastest states, up to four in the slowest, and 2–5 by standard tracked post. Australian Research Peptides' delivery checker returns an estimate against a specific postcode rather than a capital-city average. Transit figures are the carrier's, counted in business days after lodgement, and they are estimates rather than guarantees.
An 80 mg KLOW vial needs more diluent than a 10 mg peptide for the same concentration, because volume scales with milligrams and KLOW is the second-largest vial in the catalogue. Australian Research Peptides publishes no fill volume for it, and nothing else ships with the vial.
Australian Research Peptides supplies KLOW in Australia as laboratory research material and not as a medicine, so no KLOW vial is approved by the TGA or registered here for human or veterinary use. Two of the four peptides in the vial are scheduled in Australia and two, GHK-Cu and KPV, are not, which means one container holds compounds sitting in two different regulatory positions. ARP gives no legal advice; a question about a specific piece of work is one for a lawyer or a compliance adviser.
KLOW is not an approved medicine in America or in any other jurisdiction, and neither is any of its four peptides taken singly. No authority has reviewed a four-peptide mixture of this shape for safety, quality or effectiveness. Approval attaches to one defined product, made to one standard, for one stated indication. A research blend satisfies none of those conditions.
Access and regulatory questions
KLOW is banned in sport because at least two of its four peptides are — BPC-157 under S0, TB-500 among the S2 growth factors. KPV and GHK-Cu are named nowhere, which settles less than it appears. A tested competitor gains nothing from the mixture, since one prohibited component in a sample is sufficient. Sport Integrity Australia is the Australian authority.
Importing KLOW is harder to answer than importing a single compound, because one declared item covers four peptides and they do not all sit in the same position under Australian law. Not one of the four is licensed as a medicine in any country, so the personal-importation route has no foreign-approved product to point at. Australian Research Peptides holds KLOW inside Australia and posts it between two Australian addresses, which takes the border out of the transaction entirely. It does not change what the material is, or what the person holding it is responsible for.
No human safety data exists for KLOW, and none exists for any of its four peptides used as part of a blend. The published record for every component stops at cultured cells and animal models, so nothing in it describes what happens in a person. Two of the four are scheduled in Australia. Australian Research Peptides supplies KLOW for in vitro research only and makes no safety claim about it.
A KLOW certificate is not something this page is able to assert, and the reason for that is structural rather than evasive. The ARP CoA library is the only register of which products and strengths currently have a document published against them — never the grade on a listing, and never a sibling product's report. KLOW is a four-peptide blend, so any certificate for it has four components to identify rather than one. No matching certificate is currently published for this product and strength.
More questions
The KLOW blend comes from Australian Research Peptides and Chemist Warehouse does not carry it, nor does any pharmacy line resemble it. The blend brings four research peptides together in one vial and not one of them is approved for supply in Australia. ARP lists it as a single 80 mg research vial.